[go: up one dir, main page]

NO20063135L - Farmasoytiske preparater og fremgangsmater for insulinbehandling - Google Patents

Farmasoytiske preparater og fremgangsmater for insulinbehandling

Info

Publication number
NO20063135L
NO20063135L NO20063135A NO20063135A NO20063135L NO 20063135 L NO20063135 L NO 20063135L NO 20063135 A NO20063135 A NO 20063135A NO 20063135 A NO20063135 A NO 20063135A NO 20063135 L NO20063135 L NO 20063135L
Authority
NO
Norway
Prior art keywords
methods
pharmaceutical preparations
insulin therapy
insulin
therapy
Prior art date
Application number
NO20063135A
Other languages
English (en)
Other versions
NO330737B1 (no
Inventor
Robert J Gyurik
Carl Reppucci
Original Assignee
Bentley Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bentley Pharmaceuticals Inc filed Critical Bentley Pharmaceuticals Inc
Publication of NO20063135L publication Critical patent/NO20063135L/no
Publication of NO330737B1 publication Critical patent/NO330737B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20063135A 2003-12-08 2006-07-06 Farmasoytisk preparat inneholdende insulin egnet for nasal tilforse NO330737B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52772803P 2003-12-08 2003-12-08
PCT/US2004/040313 WO2005056038A1 (en) 2003-12-08 2004-12-02 Pharmaceutical compositions and methods for insulin treatment

Publications (2)

Publication Number Publication Date
NO20063135L true NO20063135L (no) 2006-09-08
NO330737B1 NO330737B1 (no) 2011-06-27

Family

ID=34676771

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063135A NO330737B1 (no) 2003-12-08 2006-07-06 Farmasoytisk preparat inneholdende insulin egnet for nasal tilforse

Country Status (19)

Country Link
US (4) US7112561B2 (no)
EP (2) EP1706128B1 (no)
JP (2) JP2007513199A (no)
KR (1) KR100978717B1 (no)
CN (2) CN1913912B (no)
AT (1) ATE474591T1 (no)
AU (2) AU2004296784B2 (no)
BR (1) BRPI0418589A (no)
CA (1) CA2547990C (no)
DE (1) DE602004028284D1 (no)
DK (1) DK1706128T3 (no)
EA (1) EA010885B1 (no)
ES (1) ES2348303T3 (no)
HK (1) HK1097464A1 (no)
IL (1) IL176015A (no)
NO (1) NO330737B1 (no)
NZ (2) NZ547587A (no)
WO (1) WO2005056038A1 (no)
ZA (1) ZA200604683B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE466611T1 (de) * 2000-04-03 2010-05-15 Battelle Memorial Institute Ausgabevorrichtungen und flüssigformulierungen
EP1343521A2 (en) * 2000-12-01 2003-09-17 Battelle Memorial Institute Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
WO2005056038A1 (en) 2003-12-08 2005-06-23 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US10835351B2 (en) 2005-06-15 2020-11-17 Alan Ara BOGHOSIAN Method of preparing dentition for the taking of a dental impression
US20060286510A1 (en) * 2005-06-15 2006-12-21 Boghosian Alan A Method of preparing dentition for the taking of a dental impression
US10231805B2 (en) 2005-06-15 2019-03-19 Alan Ara BOGHOSIAN Method of preparing dentition for the taking of a dental impression
EP1947938A4 (en) * 2005-11-02 2009-07-01 Cpex Pharmaceuticals Inc MACROCYCLIC FORMULATIONS FOR TRANSMEMBRANE DRUG DELIVERY
WO2007146126A2 (en) * 2006-06-08 2007-12-21 Cpex Pharmaceuticals, Inc. Insulin composition
US20080107735A1 (en) * 2006-11-02 2008-05-08 Gyurik Robert J Macrocyclic formulations for transmembrane drug delivery
PL2134351T3 (pl) 2007-03-13 2017-10-31 Jds Therapeutics Llc Sposoby i kompozycje do przedłużonego uwalniania chromu
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2282725A4 (en) * 2008-06-05 2012-07-04 Cpex Pharmaceuticals Inc NASAL FORMULATIONS OF INSULIN
US20100160214A1 (en) * 2008-12-22 2010-06-24 Serenity Pharmaceuticals Corporation Desmopressin composition
SG10201509152VA (en) 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
PT4104848T (pt) 2009-06-18 2024-01-04 Acerus Pharmaceuticals Usa Llc Administração segura de desmopressina
WO2011049776A1 (en) * 2009-10-22 2011-04-28 Cpex Pharmaceuticals, Inc. Therapeutically effective preparations of insulin
JP6152346B2 (ja) 2011-03-01 2017-06-21 ジェーディーエス セラピューティックス、エルエルシーＪＤＳ Ｔｈｅｒａｐｅｕｔｉｃｓ，ＬＬＣ 糖尿病、低血糖、および関連障害の治療および予防のためのインスリンとクロムの組成物
AU2014293140A1 (en) 2013-07-23 2016-03-03 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
US9814753B2 (en) 2013-07-23 2017-11-14 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3-adrenergic receptor agonist
ES2923438T3 (es) 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
EP3413900A1 (en) 2016-02-11 2018-12-19 Nutrition 21, LLC Chromium containing compositions for improving health and fitness

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211766A (en) 1972-07-10 1980-07-08 Ab Bonnierforetagen Cancer associated polypeptide antigen compositions
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1554157A (en) * 1975-06-13 1979-10-17 Takeda Chemical Industries Ltd Stable insulin preparation for intra nasal administration
GB2002795B (en) 1977-07-15 1982-03-17 Mallinckrodt Inc Nail enamel compositions their preparation and use
US5132459A (en) 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
DE19975055I1 (de) 1979-08-22 2000-01-27 Novartis Ag Propenylamine Verfahren zu ihrer Herstellung sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwending als Arzneimittel
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
EP0083305B1 (de) 1981-12-24 1985-07-10 Ciba-Geigy Ag Cyclische Octapeptide und pharmazeutische Präparate davon, sowie Verfahren zur Herstellung derselben und ihre Anwendung
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
US4760096A (en) 1985-09-27 1988-07-26 Schering Corporation Moisturizing skin preparation
WO1987002580A1 (en) 1985-11-04 1987-05-07 Dermatological Products Of Texas Film-forming, pharmaceutical vehicles for application of medicaments to nails, pharmaceutical compositions based on those vehicles, and methods of using same
DE3690626C2 (de) * 1985-12-04 1997-05-15 Dean Hsieh Arzneimittel, enthaltend neben einer wirksamen Arzneistoffmenge ein Lacton oder cyclisches Keton
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5731303A (en) * 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US4782059A (en) 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
US4894375A (en) 1986-09-29 1990-01-16 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
US5179079A (en) 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
HU200914B (en) 1987-03-09 1990-09-28 Horvath Gyoengyi Lengyelne Process for producing new medical dosage unit suitable for local treatment of fungus infection of nails
US5641475A (en) 1987-05-15 1997-06-24 Tristrata, Inc. Antiodor, antimicrobial and preservative compositions and methods of using same
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
LU86924A1 (fr) 1987-06-19 1989-03-08 Oreal Vernis a ongles anhydres
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
US5028431A (en) 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
ES2038344T3 (es) 1988-01-13 1993-07-16 Schwarz Pharma Ag Soluciones concentradas de corticoesteroides y metodo para su fabricacion.
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4920112A (en) 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US4920109A (en) 1988-04-18 1990-04-24 Merck & Co., Inc. Antifungal compositions and method of controlling mycotic infections
US5160737A (en) 1988-05-03 1992-11-03 Perio Products Ltd. Liquid polymer composition, and method of use
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
HUT58201A (en) 1989-03-03 1992-02-28 Sandoz Ag Process for producing antiphlogistic pharmaceutical composition containing naphtalene-methan-amino derivatives
FR2646603B1 (fr) 1989-05-03 1991-07-12 Oreal Composition nettoyante
US5214046A (en) 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
CA2020888A1 (en) 1989-07-27 1991-01-28 Philippe Guerry Substituted aminoalkoxybenzene derivatives
US5562608A (en) 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
EP0472858B2 (en) 1990-07-04 2000-03-15 Kao Corporation Hair treatment composition
JPH078806B2 (ja) 1990-08-16 1995-02-01 旭化成工業株式会社 カルシトニン類含有経鼻投与用乳剤
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
IT1247138B (it) 1991-03-06 1994-12-12 Dompe Farmaceutici Spa Composizione farmaceutica idrofila contenente ketoprofene sale di lisina per uso topico.
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US5437272A (en) 1991-05-01 1995-08-01 Alliance Pharmaceutical Corp. Perfluorocarbon associated gas exchange
DK0583358T3 (da) 1991-05-03 1999-08-16 Alliance Pharma Partiel væskerespiration af carbonfluorider
US6005001A (en) 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU223343B1 (hu) 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
HU219480B (hu) 1991-05-23 2001-04-28 Novartis Ag. Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
TW246682B (no) 1991-08-12 1995-05-01 Procter & Gamble
WO1993009833A1 (en) 1991-11-14 1993-05-27 Alliance Pharmaceutical Corp. Method and apparatus for partial liquid ventilation using fluorocarbons
DE4242919A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
IT1261776B (it) 1993-03-12 1996-06-03 Mendes Srl Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5661170A (en) 1994-03-21 1997-08-26 Woodward Laboratories, Inc. Antimicrobial compositions and methods for using the same
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
FR2722102B1 (fr) 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
WO1996015826A1 (en) * 1994-11-17 1996-05-30 Alza Corporation Composition and method for enhancing electrotransport agent delivery
US5696164A (en) 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
US5945409A (en) 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
GB9509631D0 (en) 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
US5667809A (en) 1995-06-07 1997-09-16 Alliance Pharmaceutical Corp. Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents
GB9513750D0 (en) 1995-07-06 1995-09-06 Sandoz Ltd Use of allylamines
FR2737118B1 (fr) 1995-07-28 1997-09-05 Oreal Composition dermatologique ou pharmaceutique, procede de preparation et utilisation
CA2231769A1 (en) 1995-09-14 1997-03-20 James L. Sorenson Composition and method for treating diseased nails
NZ280065A (en) 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
JP3263598B2 (ja) 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
KR100213465B1 (ko) 1996-11-01 1999-08-02 최좌진 케토프로펜 패취 조성물
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
JP2000516928A (ja) 1996-08-09 2000-12-19 バックマン・ラボラトリーズ・インターナショナル・インコーポレーテッド 抗真菌性化合物とｎ―アルキル複素環式化合物とを併用する真菌感染の治療
US5993787A (en) 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
ES2260802T3 (es) 1996-10-18 2006-11-01 Arizona Chemical Company Geles de poliamida terminada en esteres.
US6694975B2 (en) 1996-11-21 2004-02-24 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5898028A (en) * 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US5813416A (en) 1997-04-03 1998-09-29 Rudolph; James M. File with sanitizing agent
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6645506B1 (en) 1997-04-18 2003-11-11 Ganeden Biotech, Inc. Topical compositions containing extracellular products of Pseudomonas lindbergii and Emu oil
US5976547A (en) 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
US6482839B1 (en) 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
WO1999009997A1 (en) 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
DE69834339T2 (de) 1997-08-26 2007-05-24 Board of Regents, The University of Texas System, Austin Verwendung einer zusammensetzung die einen chelatbildner und eine antimikrobielle verbindung enthaltet zur behandlung von biofilmen
WO1999010022A2 (en) 1997-08-27 1999-03-04 California Institute Of Technology Methods and compositions to prevent formation of adhesions in biological tissues
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
EP1857113A3 (en) 1997-10-22 2007-12-19 Jens Ponikau USE OF ANTIFUNGAL AGENTS FOR THE TOPICAL TREATMENT OF asthma
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
JP2001523273A (ja) 1998-02-09 2001-11-20 マクロケム・コーポレーシヨン 抗真菌性爪ラッカーおよびそれの使用方法
US6200951B1 (en) 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
US6225075B1 (en) 1998-03-13 2001-05-01 Advanced Research And Technology Institute, Inc. DNA encoding sterol methyltransferase
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
NL1008795C2 (nl) 1998-04-02 1999-10-05 Rene Werenfridus Lodewijk Vroo Samenstelling voor het behandelen van hoeven en werkwijze voor het vervaardigen van de samenstelling.
MXPA00010068A (es) 1998-04-14 2002-08-06 Jomaa Hassan Uso de compuestos organofosforicos para el tratamiento terapeutico y preventivo de infecciones.
WO1999059543A1 (en) 1998-05-20 1999-11-25 Highchem Company., Ltd. A pharmaceutical formulation for nasal administration
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6071541A (en) 1998-07-31 2000-06-06 Murad; Howard Pharmaceutical compositions and methods for managing skin conditions
US6117119A (en) 1998-08-28 2000-09-12 Silipos, Inc. Gelatinous body protection article having a therapeutic additive
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
JP3777499B2 (ja) 1999-04-16 2006-05-24 ゼファーマ株式会社 抗真菌組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
EP1187639A1 (en) 1999-06-04 2002-03-20 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6335023B1 (en) 1999-06-30 2002-01-01 Ruey J. Yu Oligosaccharide aldonic acids and their topical use
US6403063B1 (en) 1999-07-26 2002-06-11 Kenneth I. Sawyer Method of treating nail fungus
EP1212093B1 (en) 1999-08-26 2004-07-07 Ganeden Biotech, Inc. Use of emu oil as a carrier for antifungal, antibacterial and antiviral medications
WO2001019528A1 (en) 1999-09-15 2001-03-22 Aradigm Corporation Pore structures for reduced pressure aerosolization
US6894026B1 (en) 2000-01-11 2005-05-17 Atossa Healthcare, Inc. Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
DE10011081A1 (de) 2000-03-09 2001-09-13 Aventis Pharma Gmbh Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel
US6281239B1 (en) 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
CN1211164C (zh) 2000-05-10 2005-07-20 斯凯伊药品加拿大公司 介质研磨
US6914051B1 (en) 2000-06-28 2005-07-05 David M Allen Penetrating antibiotic gel for soft tissue diseases
US6503953B2 (en) 2000-07-26 2003-01-07 Atopic Pty Ltd. Methods for treating atopic disorders
AU2001291721A1 (en) 2000-08-25 2002-03-04 Merck Patent G.M.B.H Powdered mannitol and mannitol-containing compositions
US20050032683A1 (en) 2000-10-04 2005-02-10 Amento Edward P. Methods of modulating apoptosis by administration of relaxin agonists or antagonists
EP1201738A1 (en) 2000-10-30 2002-05-02 Pfw Aroma Chemicals B.V. Fragrance composition comprising cyclohexadecanone
BR0207422A (pt) 2001-02-09 2005-04-19 Genentech Inc Cristal formado por igf-1, composição, método de tratamento de mamìferos que sofrem de disfunção de um agonista, método de cristalização de igf-1, igf-1 cristalino, métodos de identificação de agonistas indiretos de igf-1, complexo co-cristalino, método de determinação de estrutura tridimensional de igf-1, meio de armazenagem de dados legìvel por máquina, cristal de igf-1, método de uso de estrutura tridimensional de igf-1, método de identificação de agonistas ou antagonistas de igf-1, método de projeto de composto, método de identificação de peptidomimético, método de determinação de pelo menos uma parte de estrutura tridimensional de um complexo molecular, método de avaliação da capacidade de uma entidade quìmica de associar-se com igf-1, entidade quìmica, derivado de átomo pesado, método de avaliação experimental ou computacional de uma entidade quìmica e uso de uma composição
ITMI20010430A1 (it) 2001-03-02 2002-09-02 Dinamite Dipharma S P A In For Metodo per la sintesi di terbinafina
US6878365B2 (en) 2001-03-10 2005-04-12 James Edward Brehove Topical application for treating toenail fungus
US6956058B2 (en) * 2001-04-26 2005-10-18 Kao Corporation Method for improving insulin resistance
JP2004535432A (ja) * 2001-06-22 2004-11-25 ベントレー ファーマシューティカルズ インコーポレイテッド 医薬組成物
US6602496B2 (en) 2001-07-05 2003-08-05 Closure Medical Corporation Adhesive treatment for tinea corporis
US6585967B2 (en) 2001-07-05 2003-07-01 Closure Medical Corporation Adhesive treatment for tinea cruris
US6673369B2 (en) 2001-08-29 2004-01-06 Ranbaxy Laboratories Limited Controlled release formulation
AU2002364893A1 (en) 2001-10-22 2003-06-17 University Of Mississippi Delivery of medicaments to the nail
US6544950B1 (en) 2001-12-06 2003-04-08 University Of Kentucky Research Foundation Seventeen amino acid peptide (Peptide P) for treating ischemia and reperfusion injury
US20030211995A1 (en) 2001-12-21 2003-11-13 Kokai-Kun John Fitzgerald Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
KR100459275B1 (ko) 2001-12-28 2004-12-03 주식회사유한양행 터비나핀 또는 그의 염산염의 제조방법
US6899890B2 (en) 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
MY139721A (en) 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
US6958142B2 (en) 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
JP2006515629A (ja) 2003-01-23 2006-06-01 シャイア ラボラトリーズ，インコーポレイテッド 吸収促進剤
US20050069578A1 (en) 2003-08-05 2005-03-31 Balasubramanian Sathyamangalam V. Reconstitution medium for protein and peptide formulations
WO2005056038A1 (en) * 2003-12-08 2005-06-23 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment

Also Published As

Publication number Publication date
CA2547990C (en) 2011-08-02
DK1706128T3 (da) 2010-10-04
KR100978717B1 (ko) 2010-08-30
US7112561B2 (en) 2006-09-26
US20050123592A1 (en) 2005-06-09
IL176015A0 (en) 2006-10-05
KR20060117989A (ko) 2006-11-17
NZ578735A (en) 2011-06-30
NO330737B1 (no) 2011-06-27
US20090156464A1 (en) 2009-06-18
AU2004296784A1 (en) 2005-06-23
EA200601123A1 (ru) 2006-10-27
US7651996B2 (en) 2010-01-26
AU2004296784B2 (en) 2010-12-02
EP1706128A4 (en) 2008-11-26
CN1913912A (zh) 2007-02-14
JP2009292820A (ja) 2009-12-17
US8044020B2 (en) 2011-10-25
JP2007513199A (ja) 2007-05-24
ZA200604683B (en) 2007-04-25
AU2010219399A1 (en) 2010-09-30
BRPI0418589A (pt) 2008-01-29
US20070010425A1 (en) 2007-01-11
EP1706128A1 (en) 2006-10-04
EP2241326A1 (en) 2010-10-20
CN101829319A (zh) 2010-09-15
NZ547587A (en) 2009-09-25
HK1097464A1 (en) 2007-06-29
IL176015A (en) 2010-12-30
EP1706128B1 (en) 2010-07-21
DE602004028284D1 (de) 2010-09-02
ES2348303T3 (es) 2010-12-02
US20100144593A1 (en) 2010-06-10
CA2547990A1 (en) 2005-06-23
WO2005056038A1 (en) 2005-06-23
CN1913912B (zh) 2010-06-16
ATE474591T1 (de) 2010-08-15
EA010885B1 (ru) 2008-12-30

Similar Documents

Publication Publication Date Title
NO20063135L (no) Farmasoytiske preparater og fremgangsmater for insulinbehandling
EA200401525A1 (ru) Способы лечения гепатита (варианты )
CY1119029T1 (el) Θεραπευτικη αντιμετωπιση συμπαγων εγκεφαλικων νεοπλασιων με ενα παραγωγο ραπαμυκινης
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
PL397846A1 (pl) Leczenie zaburzeń związanych z TNFα
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
BR0307058A (pt) N-óxidos de derivados de n-fenil-2-pirimidina-amina
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
PL371736A1 (en) Method for administering glp-1 molecules
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
DE60330889D1 (de) Botulinum toxin zur behandlung von magengeschwür und gastroösophagealen reflux
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
ATE408601T1 (de) Fredericamycin-derivate
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
NO20062229L (no) Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er)
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
NO20054631D0 (no) Antistoff mot tumorspesifikt antigen som mal
DK1399186T3 (da) Lægemiddel til behandling af tumorer og disses metastaser under anvendelse af et bindemolekyle mod knogle-sialoprotein
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
ATE506960T1 (de) Medikament und verwendung zur tumortherapie
AU2003206144A1 (en) Pharmaceutical composition for cancer treatment containing p43 protein and paclitaxel, therapy method using the same and use thereof
CY1111320T1 (el) Cripto ειδικα αντισωματα
ATE361097T1 (de) Orale vakzinierung mit dem tumor-antigen-mimotop gln-met-trp-ala-pro-gln-trp-gly-pro-asp

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees